Home » RADIUS ANNOUNCES LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE EISAI SERMS
RADIUS ANNOUNCES LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE EISAI SERMS
June 29, 2006
Radius announced today that it has acquired exclusive worldwide rights, excluding Japan, to a new class of selective estrogen receptor modulators (SERMs) discovered by Eisai Co., Ltd. Radius is currently advancing its first development candidate from this class, RAD 1901, into pre-IND studies for the treatment and prevention of hot flashes (vasomotor symptoms) and osteoporosis. Financial terms were not disclosed.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-29-2006/0004389454&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct